‘Cell Cure’ Granted $1.3M From Israel’s Chief Scientist Office

BioTime announced that its subsidiary Cell Cure Neurosciences has been awarded a grant of 5 million NIS (approximately $1.33 million) from Israel’s Office of the Chief Scientist. The funds will help finance the development of OpRegen(R), a cell-based therapeutic product for the treatment of age-related macular degeneration – a severe form of acute vision loss and the leading cause of blindness in an aging population. Cell Cure, established in 2005 is located in Jerusalem, Israel on the campus of Hadassah University Hospital.